2 reports

Expansion through additional i ndications Diffuse large B -cell lymphoma (DLBCL) accounts for about one -third of malignant lymphoma, with patient numbers following an upward trend.

  • Lymphoma
  • Pharmaceutical
  • Japan
  • Company Financials
  • SymBio Pharmaceuticals Limited
  • Jul 27, 2017: Seattle Genetics Reports Second Quarter 2017 Financial Results
  • Apr 27, 2017: Seattle Genetics Reports First Quarter 2017 Financial Results

It is also indicated for the treatment of patients with Systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen.

  • Breast Cancer
  • Lymphoma
  • United States
  • Company Financials
  • Seattle Genetics, Inc.